This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Pharmaceuticalcompanies have responded with growing investment in the research and development of novel eye treatments and drug delivery systems designed to address key challenges in ocular therapy. Challener News Article Hydrogels, drug-eluting contact lenses, and other implant technologies show real promise. Siemens Finalizes $5.1B
The platform provides a means of technical exchange on high-quality, ready-to-fill primary packaging between pharmaceuticalcompanies, contract manufacturers, and contract development and manufacturing organizations.
It is one of the biggest investments in UK history for a pharmaceuticalcompany. The multi-year partnership with the UK government aims to provide up to 10,000 patients with investigational personalised cancer immunotherapies by 2030, according to the UK governments Department for Science, Innovation and Technology (DSIT).
In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceuticalcompanies in 2023 are assessed.
Another recent change is the timelier release of scientific information; rather than holding on to clinical trial findings until the ‘perfect’ opportunity to present them at a major congress, 2020 increasingly saw pharmaceuticalcompanies make data public in real time. What are the associated challenges? Conclusion.
Specifically, the amount spent on basic research, new treatments, vaccines, and diagnostics was $1.2 Yet this amounted to only one quarter of the $5 billion annual goal that was adopted last year at a United Nations High-Level Meeting on TB as part of a plan to end the epidemic by 2030. Meanwhile, the U.S.
Practical examples of this include healthcare professionals using VR to learn various medical procedures or for the technology to be used to teach broader society about public health issues, such as the importance of vaccination. When both ‘treatments’ were combined, the vaccination intention increased even further. The more you know.
For more than 240 years, Takeda has focused on delivering transformative treatments in the therapeutic areas of gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.
The Singapore Government has launched Biologics Pharma Innovation Programme Singapore (BioPIPS), which aims to increase the country’s manufacturing capacity for biologics, including recombinant proteins and vaccines. The organizations plan to use data analytics to improve manufacturing processes. Additionally, Merck & Co.
This includes vaccines which prevent diseases, such as for HPV papilloma, which is already part of the European plan. With 90% of adolescents that should be vaccinated by 2030, Luppi deems it an opportunity. Hence, the electronic record should be available across the breadth of patient diversity, she said.
… Sanofi plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the pharmaceuticalcompany expands its immunology pipeline, a key focus of its strategy, STAT writes. The treatment brought in $479 million in revenue in 2024, with Blueprint forecasting that sales could reach $2 billion by 2030. Sanofi
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content